Osiris Up on Q3 Earnings

Zacks

Osiris Therapeutics Inc.’s (OSIR) shares, which were up 25.1% immediately after the company reported third quarter results, were down 9.3% in the following trading session. Overall, shares are up 20.9% since the release of third quarter results. Osiris’ third quarter results were better-than-expected with the company reporting break-even earnings, well above the Zacks Consensus Estimate of a loss of 9 cents and the year-ago loss of a penny per share.

Revenues for the quarter came in at $6.9 million, in line with the Zacks Consensus Estimate and well above the year-ago quarter revenues of $2.2 million.

Research and development (R&D) expenses declined 25.3% from the year-ago period to $0.9 million. The company intends to study Grafix for the treatment of venous leg ulcers.

Selling, general and administrative expenses increased to $4 million from $0.7 million in the year-ago period due to higher commercial activities.

Meanwhile, in early Oct 2013, Osiris sold its culture-expanded mesenchymal stem cell (ceMSC) business including Prochymal (for up to $100 million) to a wholly-owned subsidiary of Mesoblast Limited. Osiris will be entitled to royalty payments as well.

Osiris also stated that the FDA does not require the company to file a biologic license application (:BLA) for Grafix to remain on the market. However, the company intends to submit a BLA for enhanced label claims in the next 12-18 months.

Osiris intends to continue investing in its sales force and expects to have about 50 sales reps promoting Grafix within the next 6 months.

Osiris is a Zacks Rank #4 (Sell) stock. At present, companies like Actelion Ltd. (ALIOF), AMAG Pharmaceuticals, Inc. (AMAG) and Isis Pharmaceuticals, Inc. (ISIS) look well-positioned with all three carrying a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on ISIS
Read the Full Research Report on ALIOF
Read the Full Research Report on AMAG
Read the Full Research Report on OSIR


Zacks Investment Research

View Comments (0)